Icatibant Zentiva (Icatibant Acetate)

Icatibant acetate is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms causing the rapid swelling seen in hereditary angioedema attacks.

The dosage of Icatibant Zentiva is determined by the prescribing clinician based on the patient’s condition, weight, and severity of the HAE attack. The prescriber will specify the exact amount, frequency, and duration of treatment.

Safety data for icatibant acetate in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing it to pregnant or breastfeeding individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Icatibant Zentiva is a bradykinin B2 receptor antagonist, whereas other HAE therapies may target C1‑esterase inhibitor replacement or kallikrein inhibition. Icatibant offers a subcutaneous, rapid‑acting option that directly blocks bradykinin, making it useful for patients who prefer self‑administration and need quick symptom control.

Icatibant Zentiva should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use the medication if it has been exposed to temperatures outside the recommended range.

The medication is supplied as a sterile injection solution for subcutaneous use. A healthcare professional or trained patient injects the prescribed dose into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique and the instructions provided by the prescriber.

Serious risks include anaphylaxis, severe hypersensitivity reactions, unexpected angioedema of the face or airway, and sudden hypotension. Patients should be monitored closely after injection, and any signs of severe allergic reaction or rapid swelling should prompt immediate medical attention.

Icatibant Zentiva is contraindicated in individuals with known hypersensitivity to icatibant acetate or any of the formulation excipients. Patients with a history of severe allergic reactions to bradykinin B2 antagonists should avoid its use.